TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 1nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 2nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 4nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 4nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 4nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 5nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 5nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 7nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 7nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 8nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 8nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 9nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 10nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 12nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 13nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 13nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 13nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 14nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 14nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 16nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 16nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 17nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 17nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 18nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 18nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 19nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 23nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 23nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 24nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 24nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 25nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 27nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 28nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 30nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 30nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 30nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 33nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 34nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 34nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 36nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 38nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 41nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 45nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 46nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 48nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 52nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 53nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 54nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 56nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase pim-1(Homo sapiens (Human))
Sumitomo Dainippon Pharma Oncology
US Patent
Sumitomo Dainippon Pharma Oncology
US Patent
Affinity DataIC50: 58nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair